



ASCO 2025 TIP SHEET

Oral Presentations (9)

Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.

*Dr. **C. Ola Landgren** is first and presenting author.*

A novel virtual reality supportive care intervention (BMT-VR) for patients undergoing hematopoietic stem cell transplantation (HSCT): A pilot randomized clinical trial.

***Lara Traeger, Ph.D.**, is a co-author.*

Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).

*Dr. **Gerald Soff** is a co-author.*

Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.

*Dr. **Jaime Merchan** is a co-author.*

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.

*Dr. **Gina D'Amato** is a co-author.*

A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.

*Dr. **Jose Lutzky** is a co-author. (Late-Breaking Abstract)*

Psychosocial digital application for caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT): A randomized controlled trial.

*Dr. **Lara Traeger** is a co-author.*

Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

*Dr. **Leonel Hernandez-Aya** is a co-author.*

A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).

*Dr. **Jonathan Trent** is a co-author.*

Rapid Oral Presentations (4)

Escalating impact of alcohol-related cancer mortality in the US: A call for action.

Chinmay Jani is first and presenting author and Dr. **Gilberto Lopes** is senior author.

The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.

Dr. **Michele Ceccarelli** is a co-author.

Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.

Dr. **Gilberto Lopes** is a co-author.

Improve update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).

Dr. **Terrence Bradley** is a co-author.

Special Sessions (3)

Oncologic Surgeon Perspective (Case-Based Panel)

Dr. **Francis Hornicek** is a panelist.

Emerging Therapeutics for Patients with Brain Tumors and Rare Oncogenic Drivers (Education Session)

Dr. **Antonio Iavarone** is the presenter.

Is Pancreas Subtyping Ready for Prime Time? (Clinical Science Symposium)

Dr. **Peter Joel Hosein** leads the abstracts discussion.

Poster Presentations (51)

Ethnic disparities in unmet supportive care needs and outcomes among older ambulatory cancer patients.

Frank Penedo, Ph.D., is first and presenting author.

Use of brain protein I3 (BRI3) to predict disease fate in glioblastoma.

Dr. **Ifeanyichukwu Ogbuoro** is first and presenting author.

Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).

Dr. **Clara Oh** is first and presenting author.

Advancing evidence-based NSCLC testing and treatment across academic and community-based settings.

Dr. **Gilberto Lopes** is first and presenting author.

Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.

Dr. **Gilberto Lopes** is first and presenting author.

Environmental PFAS exposure as an understudied social determinant of health for endometrial cancer disparities: A geospatial study in Florida.

*Dr. **Ming Sheng Lee** is first and presenting author.*

Women's breast cancer mortality trends: The impact of lifestyle factors from the 2021 Global Burden of Disease (GBD) study.

*Dr. **Samantha El Warrak** is first and presenting author.*

Characterizing unmet supportive care needs in diverse adolescent and young adult cancer survivors.

*Dr. **Akina Natori** is first and presenting author.*

Transforming genomic testing in prostate cancer: A comprehensive system-wide initiative.

*Dr. **Chinmay Jani** is first and presenting author.*

Matching-adjusted indirect comparison (MAIC) of olutasidenib (OLU) and ivosidenib (IVO) in isocitrate dehydrogenase 1 (IDH1)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML).

*Dr. **Justin M. Watts** is first and presenting author.*

Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.

*Dr. **Justin M. Watts** is first and presenting author.*

Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC).

*Dr. **Dan Morgenstern Kaplan** is first and presenting author.*

Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).

***Richa Dawar** is first author and Dr **Gilberto Lopes** is presenting author.*

A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with osseous metastases (RADICAL/Alliance A031801).

*Dr. **Chinmay Jani** is first and presenting author.*

Enhancing soft tissue sarcoma surveillance: The role of ctDNA testing in early detection and monitoring beyond traditional imaging.

*Dr. **Amrit Paudel** is first and presenting author.*

Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter?

*Dr. **Gilberto Lopes** is a co-author.*

DAREONTM-9, a phase Ib study of obixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results.

*Dr. **Aman Chauhan** is a co-author.*

Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, comprehensive genomic study of desmoids and CTNNB1/APC mutated soft tissue tumors.

*Dr. **Gina D'Amato** is a co-author.*

Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.

*Drs. **Steve Bialick**, **Gina D'Amato** and **Jonathan Trent** are co-authors.*

SARC044: A phase II trial of bezucastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy.

*Dr. **Steve Bialick** is a co-author.*

An open-label phase 1/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor.

*Dr. **Jonathan Trent** is a co-author.*

PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

*Dr. **Gilberto Lopes** is the senior co-author.*

Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).

*Dr. **Jonathan Trent** is a co-author.*

ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.

*Dr. **Emily Jonczak** is a co-author.*

FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.

*Dr. **Macarena De La Fuente** is a co-author.*

Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.

*Dr. **Gilberto Lopes** is a co-author.*

State-level trends and associated disparities in melanoma burden in the United States.

*Dr. **Chinmay Jani** is a co-author.*

Disparities in exercise referral practices and barriers among oncologists in public and private institutions in Latin America.

*Dr. **Gilberto Lopes** is a co-author.*

A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.

*Dr. **Justin M. Watts** is the senior co-author.*

Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).

*Dr. **Mikael Sekeres** is a co-author.*

Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

*Dr. **James Hoffman** is a co-author.*

The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory Merkel cell carcinoma.

*Dr. **Jose Lutzky** is a co-author.*

Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck.

*Dr. **Donald Weed** is a co-author.*

MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.

*Dr. **Priscila Barreto Coelho** is a co-author.*

Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.

*Dr. **Carmen Calfa** is the senior co-author.*

Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Final data from the ARROW trial.

*Dr. **Gilberto Lopes** is a co-author.*

Racial and socioeconomic disparities in testicular cancer survival outcomes: A SEER database analysis.

*Dr. **Chinmay Jani** is the senior co-author.*

A phase I and randomized phase II trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase I results.

*Drs. **Russ Kuker**, **Savita Dandapani** and **Steven Gore** are co-authors.*

Prospective monitoring of prostate specific membrane antigen-positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up.

*Dr. **Marijo Bilusic** is a co-author.*

Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial.

*Dr. **Elizabeth Franzmann** is the senior co-author.*

BRAF-V600E papillary thyroid cancer: Updated analysis of real-world patient data.

*Dr. **Chukwuemeka Ikpeazu Sr.** is a co-author.*

Disparities in receipt of palliative treatments among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.

*Dr. **Brandon Mahal** is a co-author.*

Update on phase III pivotal trial of Bria-IMT + CPI vs physician's choice in advanced metastatic breast cancer (BRIA-ABC).

*Dr. **Lawrence Negret** is a co-author.*

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma.

*Dr. **Leonel Hernandez-Aya** is a co-author.*

Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.

*Dr. **Marijo Bilusic** is a co-author.*

Trial in progress: A first-in-human (FIH) phase I study of PTX-912 in patients with locally advanced or metastatic solid tumors.

*Drs. **Marijo Bilusic** and **Chinmay Jani** are co-authors.*

TUB-030, a novel ADC targeting 5T4: A phase I/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors.

*Dr. **Jaime Merchan** is a co-author.*

A phase II study of niraparib (N), abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa; HARMONY).

*Dr. **Marijo Busilic** is a co-author.*

NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study.

*Dr. **Gilberto Lopes** is a co-author.*

Independent validation of a 16-protein test to assess malignant potential of small uveal melanocytic tumors.

*Dr. **J. William Harbour** is the senior co-author.*

A phase 3 randomized study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in locoregional recurrent head and neck squamous cell carcinoma (HNSCC).

*Dr. **Franciso Civantos** is a co-author.*

EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.

Dr. Benjamin Spieler is a co-author.

Publication-Only Abstracts (31)

For a complete list of the publication-only abstracts, please email [**sandy.van@miami.edu**](mailto:sandy.van@miami.edu).

#

MEDIA CONTACT:

Sandy Van

[**sandy.van@miami.edu**](mailto:sandy.van@miami.edu)